We have shown that targeting FAK kinase activity has the potential to modulate intra-tumoral Treg levels, resulting in robust CD8+ T cell anti-tumor immunity, while others have reported previously that FAK kinase inhibitors block monocyte/macrophage and cancer-associated fibroblast recruitment into tumors by virtue of FAK’s role in regulating their migration (Stokes et al., 2011). Here, CD8A is linked to cancer.